PRQR (ProQR Therapeutics NV) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRQR ProQR Therapeutics NV PRQR
48 GF Score
Price $1.72
GF Value $2.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PRQR
48GF Score
ProQR Therapeutics NV PRQR
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ProQR Therapeutics NV (PRQR) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of $1.72 is trading 16.1% below its estimated GF Value™ of $2.05. GuruFocus considers ProQR Therapeutics NV to be Modestly Undervalued.

Key valuation signals for PRQR:

  • Short Ratio:
  • GF Value™: $2.05 vs. price of $1.72 (16.1% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the PRQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges 0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
48GF Score

Get the complete analysis for PRQR

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price
$2.05
GF Value